Complications and Clinical Outcomes of Zygomatic Implants Placed in Diabetic Patients: A Systematic Review
International Journal of Drug Delivery Technology · 05.05.2026 · 16 (24s)
DOI: 10.25258/ijddt.16.24s.18 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 05.05.2026. Verfasst von Dr. Saket Asamwar und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
To systematically review complications, survival rates, and clinical outcomes of zygomatic implants (ZIs) placed in patients with diabetes mellitus (DM).
Methods
A systematic search was conducted in PubMed, Cochrane Library, and Google Scholar for clinical studies published until 2025. PRISMA guidelines were followed. Primary outcomes included implant survival rate, marginal bone loss (MBL), and complication rates (sinusitis, peri-implantitis, infraorbital nerve injury). Secondary outcomes were patient-reported quality of life (OHIP-14) and radiographic findings. Risk of bias was assessed using RoB 2.0 and ROBINS-I tools.
Results
Fourteen studies involving 1,232 diabetic patients (with 2,847 implants) were included. The pooled 5-year survival rate of ZIs in diabetic patients was 94.7% (95% CI: 92.1–96.7%), which was slightly lower than the 97.3% (95% CI: 96.0–98.3%) in non-diabetic historical cohorts (p=0.02). Diabetic patients had a significantly higher risk of postoperative sinusitis (OR=2.45, 95% CI: 1.38–4.34) and peri-implantitis (OR=3.12, 95% CI: 1.89–5.15). Poorly controlled diabetes (HbA1c >8%) was associated with a 3.5-fold increase in implant failure (RR=3.52, 95% CI: 2.01–6.15). Immediate loading protocols showed high survival (98.1%) even in diabetics.
Conclusions
Zygomatic implant therapy remains a robust solution for the edentulous diabetic patient with significant bone loss, demonstrating favorable longitudinal survival. The primary challenge lies in the patient's altered immune response, which, if glycemic control is lax, predisposes the zygomatic site to sinusitis and peri-implant soft tissue breakdown. Success is largely contingent on a strict HbA1c threshold of 7.5% and a rigorous perioperative antibiotic regimen. Furthermore, the literature supports the viability of immediate loading, suggesting it is a functional and safe approach for this population when systemic health is stabilized.
Zitieren
APA
Asamwar, D. S., Jayesh, D. R., Sreedevi, D. V., Bondwal, D. B., Sivakumar, D. K., & E, D. S. (2026). Complications and Clinical Outcomes of Zygomatic Implants Placed in Diabetic Patients: A Systematic Review. International Journal of Drug Delivery Technology, 16(24s). https://doi.org/10.25258/ijddt.16.24s.18
Vancouver
Asamwar DS, Jayesh DR, Sreedevi DV, Bondwal DB, Sivakumar DK, E DS. Complications and Clinical Outcomes of Zygomatic Implants Placed in Diabetic Patients: A Systematic Review. International Journal of Drug Delivery Technology. 2026;16(24s). doi:10.25258/ijddt.16.24s.18
BibTeX
@article{Asamwar2026,
author = {Asamwar, Dr. Saket and Jayesh, Dr. Raghavendra and Sreedevi, Dr. V. and Bondwal, Dr. Bhavya and Sivakumar, Dr. Kirthieka and E, Dr. Selvamani},
title = {Complications and Clinical Outcomes of Zygomatic Implants Placed in Diabetic Patients: A Systematic Review},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {24s},
doi = {10.25258/ijddt.16.24s.18}
}
EUVIMED